Porton Pharma Solutions and BioDuro announce strategic alliance

Porton Pharma Solutions, a leading provider of custom, cross lifecycle active pharmaceutical ingredient (API) development and cGMP manufacturing services to the global drug industry, and BioDuro LLC, a leading global life sciences contract research, development and manufacturing organisation, have announced a strategic alliance and comarketing partnership

Under this agreement, Porton will incorporate BioDuro’s extensive array of unique technologies and expert resources in drug discovery (from lead compound ID and lead optimisation to clinical candidate nomination), and BioDuro’s expert formulations development and cGMP manufacture of clinical trial materials (CTMs) into Porton’s range of solutions to address complex process scale-up challenges for IND-enabling studies.

BioDuro will promote and market Porton’s extensive and proven capabilities for pilot and large-scale cGMP production of custom APIs and drug intermediates.

“We are very excited about our collaboration with BioDuro as we complement each other’s capabilities and share an industry reputation for scientific and technical expertise, excellence in operational performance and a client-centric culture," said Oliver Ju, CEO of Porton.

"Together, we can offer our global customers compelling benefits in the form of robustly integrated solutions, compressed drug development timelines and a highly efficient supply chain across the product lifecycle.”

“Our partnership with Porton further expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programmes from discovery to clinical development,” added Cyrus K. Mirsaidi, BioDuro’s President and CEO.

“Porton’s global footprint and proven track record with many of the world’s leading pharmaceutical companies will provide substantiated channels for timely and reliable delivery of high value therapeutics, using innovative and cost effective manufacturing routes, backed by high-quality assets in Asia and North America.”

Companies